Komori
Fuso Pharmaceutical Industries (4538) · InitiativeAdvanced

Strengthening the Financial Base Through Syndicated Loans

First written in FY2024. 3 of 4 entries say "Advanced", first in FY2025. Latest entry: FY2026.

4entries
3years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025 – FY20262024: 120242025: 120252026: 22026
Same theme, other companies
Funding Stabilization and Financing Cost Reduction through Syndicated LoansA theme 17 companies write about · 0 as a headwind · 17 as a tailwind

The whole theme swung hardest in 2018: 1 of 7 companies on the "Worse" side.

7 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 17 companies compared. The sentences above are computed from all 17.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「4. As of 31 March 2026, the company has entered into a syndicated loan agreement totaling ¥13.4 billion arranged by Sumitomo Mitsui Banking Corporation. The repayment date is 28 February 2039, and there is no outstanding borrowing balance or collateral at the end of the period.」

    The company entered into a syndicated loan agreement totaling ¥13.4 billion, with a repayment date of 28 February 2039, to finance construction of the Okayama No. 2 Plant.
  2. 2026-03-31AdvancedTimely disclosure

    「We decided to raise funds through a syndicated loan.」

    The company decided to raise ¥13.4 billion through a committed term loan to fund the establishment of a new powder dialysis-agent production line and related initiatives.
  3. FY2025AdvancedAnnual report

    「On 13 May 2024, we entered into a syndicated loan agreement arranged by Sumitomo Mitsui Banking Corporation, as business expansion is expected to increase working capital requirements. The agreement is intended to establish a stronger financial base and reduce financing costs, and we carried out the financing.」

    The company disclosed that it carried out financing under the syndicated loan entered into in the previous fiscal year to address working capital requirements associated with business expansion. The contractual borrowing balance is ¥18.0 billion, and the repayment date is 31 May 2027.
  4. FY2024First statedAnnual report

    「On 13 May 2024, we entered into a syndicated loan agreement arranged by Sumitomo Mitsui Banking Corporation, as business expansion is expected to increase working capital requirements. The agreement is intended to establish a stronger financial base and reduce financing costs.」

    On 13 May 2024, the company entered into a syndicated loan agreement to address working capital requirements associated with business expansion, strengthen its financial base, and reduce financing costs.
Moved together

"Greater market penetration and stronger sales of core dialysis-related products" moved the same way as this thread, in the same document, in 3 of its 4 moves.

32★12
  1. ★This thread
  2. 1Greater market penetration and stronger sales of core dialysis-related products3×
  3. 2Response to the Generic Drug Market and Sales Promotion2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet. It last moved in the Timely disclosure of 2026-03-31: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening the Financial Base Through Syndicated Loans | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori